Gosset Flamingo Therapeutics General Information
Flamingo Therapeutics has advanced its lead antisense oligonucleotide danvatirsen into a randomized international Phase II trial in combination with pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma. Early results show clinical activity. A separate investigator-led Phase I study evaluates danvatirsen as monotherapy and with venetoclax in relapsed/refractory AML/MDS. The company’s second asset, FLM‑7523 targeting MALAT1 lncRNA, is IND-ready to enter first-in-human studies targeting solid tumors.
Contact Information
Belgium
Drug Pipeline
Key Partnerships
Merck & Co., Inc. – using pembrolizumab/KEYTRUDA® as combination partner in clinical trials., Ionis Pharmaceuticals – original discoverer of danvatirsen licensed to Flamingo., Academic partnerships with Montifore Einstein Comprehensive Cancer Center and MD Anderson Cancer Center on investigator-led trials.
Flamingo Therapeutics Funding
No funding data available